发文分析
近年国家/地区发文量统计
| 国家/地区 | 数量 |
|---|---|
| USA | 353 |
| CHINA MAINLAND | 289 |
| Italy | 210 |
| England | 139 |
| GERMANY (FED REP GER) | 89 |
| France | 77 |
| Spain | 65 |
| Japan | 54 |
| Australia | 42 |
| Canada | 40 |
近年机构发文量统计
| 机构 | 数量 |
|---|---|
| UNIVERSITY OF TEXAS SYSTEM | 49 |
| UNICANCER | 43 |
| PFIZER | 40 |
| HARVARD UNIVERSITY | 35 |
| SHANDONG FIRST MEDICAL UNIVERSITY & SHANDONG A... | 28 |
| SUN YAT SEN UNIVERSITY | 27 |
| UNIVERSITY OF LONDON | 27 |
| FUDAN UNIVERSITY | 26 |
| UNIVERSITY OF CALIFORNIA SYSTEM | 26 |
| FONDAZIONE IRCCS ISTITUTO NAZIONALE TUMORI MIL... | 25 |
近年文章引用他刊数据
| 文章名称 | 引用次数 |
|---|---|
| An overview of meningiomas | 36 |
| HALO-109-301: a Phase III trial of PEGPH20 (with gemcita... | 28 |
| Sequential afatinib and osimertinib in patients with EGF... | 25 |
| Sequential treatment with afatinib and osimertinib in pa... | 25 |
| Risk-benefit of dexrazoxane for preventing anthracycline... | 25 |
| KEYNOTE-590: Phase III study of first-line chemotherapy ... | 24 |
| Sipuleucel-T for the treatment of prostate cancer: novel... | 19 |
| Isatuximab plus pomalidomide/dexamethasone versus pomali... | 19 |
| Optimizing outcomes in EGFR mutation-positive NSCLC: whi... | 18 |
| A Phase II study of the safety and efficacy oflenvatinib... | 16 |
近年被他刊引用数据
| 期刊名称 | 引用次数 |
|---|---|
| FUTURE ONCOL | 131 |
| CANCERS | 120 |
| INT J MOL SCI | 93 |
| FRONT ONCOL | 65 |
| SCI REP-UK | 65 |
| ONCOTARGETS THER | 56 |
| CANCER MANAG RES | 51 |
| ONCOL LETT | 51 |
| MEDICINE | 49 |
| BMC CANCER | 45 |